- Home
- GALT vs EICA Comparison
GALT vs EICA Comparison
Compare GALT & EICA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GALT
- EICA
- Stock Information
- Founded
- GALT 2000
- EICA N/A
- Country
- GALT United States
- EICA
- Employees
- GALT N/A
- EICA N/A
- Industry
- GALT Biotechnology: Pharmaceutical Preparations
- EICA Finance/Investors Services
- Sector
- GALT Health Care
- EICA Finance
- Exchange
- GALT Nasdaq
- EICA Nasdaq
- Market Cap
- GALT 83.5M
- EICA N/A
- IPO Year
- GALT N/A
- EICA 2021
- Fundamental
- Price
- GALT $2.80
- EICA $24.41
- Analyst Decision
- GALT Buy
- EICA
- Analyst Count
- GALT 2
- EICA 0
- Target Price
- GALT $6.00
- EICA N/A
- AVG Volume (30 Days)
- GALT 1.5M
- EICA N/A
- Earning Date
- GALT 08-12-2025
- EICA N/A
- Dividend Yield
- GALT N/A
- EICA N/A
- EPS Growth
- GALT N/A
- EICA N/A
- EPS
- GALT N/A
- EICA N/A
- Revenue
- GALT N/A
- EICA N/A
- Revenue This Year
- GALT N/A
- EICA N/A
- Revenue Next Year
- GALT N/A
- EICA N/A
- P/E Ratio
- GALT N/A
- EICA N/A
- Revenue Growth
- GALT N/A
- EICA N/A
- 52 Week Low
- GALT $0.73
- EICA N/A
- 52 Week High
- GALT $3.90
- EICA N/A
- Technical
- Relative Strength Index (RSI)
- GALT 67.38
- EICA 52.06
- Support Level
- GALT $2.07
- EICA $24.39
- Resistance Level
- GALT $2.36
- EICA $24.63
- Average True Range (ATR)
- GALT 0.24
- EICA 0.10
- MACD
- GALT 0.03
- EICA 0.01
- Stochastic Oscillator
- GALT 81.11
- EICA 40.87
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About EICA Eagle Point Income Company Inc. 5.00% Series A Term Preferred Stock due 2026
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.